Skip to main content

As Expected, Sequenom Secures $33M Through Private Stock Placement

NEW YORK, June 7 (GenomeWeb News) - Sequenom yesterday said it secured $33 million in a private stock placement with four institutional investors.


Sequenom shareholders approved the placement and a reverse stock split last month. The stock split went into effect last week.


As part of the placement, Sequenom sold or issued around 20 million shares of common stock and warrants to purchase an additional 12 million shares.


The investors were Pequot Private Equity Fund, ComVest Investment Partners, LB I Group, and Siemens Venture Capital. Oppenheimer & Co. served as the placement agent.


Sequenom said it will use the cash for general working capital purposes, to "strengthen and expand" its core product sales and services business, and pursue opportunities in the field of non-invasive prenatal diagnostics.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.